Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning
- PMID: 27536161
- PMCID: PMC4973720
- DOI: 10.2147/IJWH.S89315
Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning
Abstract
Background: A myriad of interventions exist to treat postpartum hemorrhage (PPH), ranging from uterotonics and hemostatics to surgical and aortic compression devices. Nonetheless, PPH remains the leading cause of maternal mortality worldwide. The purpose of this article is to review the available evidence on the efficacy of misoprostol for the treatment of primary PPH and discuss implications for health care planning.
Data and methods: Using PubMed, Web of Science, and GoogleScholar, we reviewed the literature on randomized controlled trials of interventions to treat PPH with misoprostol and non-randomized field trials with controls. We discuss the current knowledge and implications for health care planning, especially in resource-poor settings.
Results: The treatment of PPH with 800 μg of misoprostol is equivalent to 40 IU of intravenous oxytocin in women who have received oxytocin for the prevention of PPH. The same dose might be an option for the treatment of PPH in women who did not receive oxytocin for the prevention of PPH and do not have access to oxytocin for treatment. Adding misoprostol to standard uterotonics has no additional benefits to women being treated for PPH, but the beneficial adjunctive role of misoprostol to conventional uterotonics is important in reducing intra- and postoperative hemorrhage during cesarean section.
Conclusion: Misoprostol is an effective uterotonic agent in the treatment of PPH. Clinical guidelines and treatment protocols should be updated to reflect the current knowledge on the efficacy of misoprostol for the treatment of PPH with 800 μg sublingually.
Keywords: PPH treatment; cesarean section; low-resource settings; retained placenta; uterotonics.
Similar articles
-
Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage.J Obstet Gynaecol Can. 2009 Oct;31(10):980-993. doi: 10.1016/S1701-2163(16)34329-8. J Obstet Gynaecol Can. 2009. PMID: 19941729 Review.
-
Prevention of postpartum hemorrhage in low-resource settings: current perspectives.Int J Womens Health. 2013 Nov 13;5:737-52. doi: 10.2147/IJWH.S51661. eCollection 2013. Int J Womens Health. 2013. PMID: 24259988 Free PMC article. Review.
-
Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan.BMC Pregnancy Childbirth. 2008 Aug 21;8:40. doi: 10.1186/1471-2393-8-40. BMC Pregnancy Childbirth. 2008. PMID: 18718007 Free PMC article. Clinical Trial.
-
An Implementation Research Study on Uterotonics Use Patterns and Heat-stable Carbetocin Acceptability and Safety for Prevention of Postpartum Hemorrhage in Nigeria.Int J MCH AIDS. 2024 Sep 23;13(Suppl 1):S38-S45. doi: 10.25259/IJMA_1_2024. eCollection 2024 Sep. Int J MCH AIDS. 2024. PMID: 39629305 Free PMC article.
-
The efficacy of intrauterine misoprostol during cesarean section in prevention of primary PPH, a randomized controlled trial.J Matern Fetal Neonatal Med. 2020 May;33(9):1459-1465. doi: 10.1080/14767058.2018.1519796. Epub 2018 Sep 26. J Matern Fetal Neonatal Med. 2020. PMID: 30176758 Clinical Trial.
Cited by
-
The effect of oxytocin, sublingual, and intrauterine misoprostol on blood loss in cesarean delivery: A randomized clinical trial.Eur J Obstet Gynecol Reprod Biol X. 2025 Feb 3;25:100369. doi: 10.1016/j.eurox.2025.100369. eCollection 2025 Mar. Eur J Obstet Gynecol Reprod Biol X. 2025. PMID: 39995616 Free PMC article.
-
The Emergent Pelvic Artery Embolization in the Management of Postpartum Hemorrhage: A Systematic Review and Meta-analysis.Obstet Gynecol Surv. 2021 Apr;76(4):234-244. doi: 10.1097/OGX.0000000000000887. Obstet Gynecol Surv. 2021. PMID: 33908615 Free PMC article.
-
Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting.Int J Womens Health. 2016 Nov 2;8:647-650. doi: 10.2147/IJWH.S119232. eCollection 2016. Int J Womens Health. 2016. PMID: 27843354 Free PMC article.
-
Uterine balloon tamponade as an adjunct to misoprostol for the treatment of uncontrolled postpartum haemorrhage: a randomised controlled trial in Benin and Mali.BMJ Open. 2017 Sep 1;7(9):e016590. doi: 10.1136/bmjopen-2017-016590. BMJ Open. 2017. PMID: 28864699 Free PMC article. Clinical Trial.
-
The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review.Syst Rev. 2018 Oct 20;7(1):170. doi: 10.1186/s13643-018-0832-4. Syst Rev. 2018. PMID: 30342555 Free PMC article.
References
-
- Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–e333. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical